
Πέμπτη 14 Δεκεμβρίου 2023 Μεταπτυχιακό Μάθημα:

Κυτταροκαλλιέργιες


Κουρεπίνη Ευαγγελία, PhD. Εθνικό Ίδρυμα Ερευνών

# Animal Cell Culture Definition, Types, Cell Lines, Procedure, Applications




cell culture

Allows researchers to grow Cells outside the body






## **Research tools**





The HEp-2 Cell line, which is a native protein array with hundreds of antigens, provides an ideal substrate for the detection of ANA

## **Diagnostic tools**



An ANA (anti nuclear antigen) test looks for antinuclear antibodies in your blood. If the test finds antinuclear antibodies in your blood, it may mean you have an autoimmune disorder.






### Systemic lupus erythematosus (SLE)



## **History**

-1907 Ross Harrison: Showed development of nerve fibers from frog embryo tissue

in vitro.




- 1912 Alexis Carrel: Kept fragments of chicken embryo heart alive and discovered cell passaging/sub-culturing.
- Till 1950 mainly tissue explants were used for culture techniques. After this year dispersed cells in cell culture media were used.

## **Cell culture**

Removal of cells of an animal or plant and their subsequent growth in a favorable artificial environment.


A) Primary cells: Passage by sub-culturing.B) Cell line: Infinite, continuous.




### HeLa: The most commonly used cell line

In the early 1980s, German virologist Harald zur Hausen found that HeLa cells contained multiple copies of human papillomavirus 18 (HPV-18), a strain of HPV later found to cause the type of cervical cancer that killed Lacks.

ATCC Number: CCL-2 Designation: HeLa







Low Density

m High Density


Scale Bar = 10





Cancer research initiatives, such as the Cancer Genome Atlas, prefer to use primary cells rather than cell lines to sequence cancer genomes because they are more biologically relevant.

## **Research tools**



## Equipment

Particular conditions of treatment and culture: temperature, air in a sterile incubator, sterile laminar flow hood, water bath, centrifuge etc.





## Cell Culture Media



There are six main ingredients
found in cell culture media:
1.Carbon source (e.g., glucose).
2.Buffering system (e.g., HEPES).
3.pH Indicator (e.g., phenol red).
4.Serum.
5.Metabolites, vitamins, minerals
and secrets (e.g. 2-me).
6.Antibiotics.

### Standard Operating Procedures (SOP) for Cell Culture Room

### November 2023

The policies outlined here are to be used for common routine maintenance and cleaning of the cell culture facilities in National Hellenic Research Foundation.

#### General

- <u>Wear clean laboratory coats</u>, not contaminated with blood or any other animal tissue.
- <u>Wear gloves</u>. Dispose of gloves when overtly contaminated or when the integrity of the glove is compromised. This is crucial as specific assays will utilize immune cells which are sensitive to activation even with remnants of dermal cells, dust, etc. Do not wear disposable gloves for touching "clean" surfaces (keyboards, telephones, etc.), and do not wear them outside the lab.

Important: gloves should be passed with 70% ethanol when they come in contact with surfaces outside of the hood.

- All bench and work areas should be kept clean with as few items and pieces of equipment as possible. Keep the access door for the culture rooms closed when the incubator door is open and/or the hoods are operating.
- No items should be stored inside the hoods unless the supplies are off the surface of the hood (Exception: sterile pipettes, tips).
- Wipe down with 70% ethanol for <u>every</u> item placed in the hood such as pipetting devices, bottles of pre-warmed media, aliquots, ice buckets, tip boxes etc.


#### To be done daily

- Hood and bench work surfaces (including microscope working areas) must be cleaned and wiped down with water and then 70% ethanol before and after every use.
- If full, biohazard bags and other trash receptacles must be sealed and removed from the lab at the end of the workday and a new empty bag placed in the receptacle. When a bag is full, specific cleaning personnel (Anastasia) should be aware to sent it or sterilization.
- Important: Glass pasteur pipettes must be sent for sterilization by the person that finishes the box. After sterilization, the box must be dried in the oven of Chemical Carcinogenesis lab.
- The incubator's temperature and CO2 readings should be confirmed in the morning and before placing any cell culture dishes.
- <u>The most important for our experiments</u>: please be extremely careful with the microscope as the lamp is very easily overheated, thus be sure that when you leave the microscope (even for some minutes) the microscope is closed, in order to avoid the destruction of the lamp that is very expensive/ time-consuming to be replaced.
- Do not forget to turn off the vacuum pump motor when it is not used (e.g. during trypsinization).

Good Cell Culture Practice (GCCP), an effort to develop minimum quality standards applicable in academia.

A major reason for the current reproducibility crisis in life sciences is the poor implementation of quality control measures and reporting standards **>** Improvement is needed, especially regarding increasingly complex in vitro methods.

- Development of induced pluripotent stem cells (iPSCs) and gene-edited cells.
- Human stem-cell-derived models and bioengineering of organo-typic cell cultures.
- Including organoids, organ-on-chip and human-on-chip approaches.



→ Not only are most experiments not reproduced, most are probably not reproducible.

### The culprit: carelessness and hubris in the drive to make a historic discovery.


#### Haruko Obokata

The spectacular fall of the scientist who claimed to have triggered stem cell abilities in regular body cells is not uncommon in the scientific community. Stap cells.




#### **Alexis Carrel**

Surgeon and biologist who was awarded the Nobel Prize in Physiology of Medicine in 1912 for pioneering vascular suturing techniques. He invented the first perfusion pump with Charles A. Lindberghn opening the way to organ transplantation.




### **Stem cell cultures**

Thomson JA et al, **"Embryonic stem cell lines derived from human blastocysts."** Science **1998** Nov 6;282(5391):1145-7.




H9 cell line: XX, normal karyotype

- <u>Origin</u>: 'Fetus after IVF, informed consent
- <u>Number of passages</u>: 32, 8 months



ES colonies (3 days in vitro culture)






Dr. Shinya Yamanaka, PhD

### Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors

Kazutoshi Takahashi<sup>1</sup> and Shinya Yamanaka<sup>1,2,\*</sup> Cell *126*, 663–676, August 25, 2006



iPS-MEF4-7




Cell



#### Dr. Kazutoshi Takahashi, PhD

### Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors

Kazutoshi Takahashi,<sup>1</sup> Koji Tanabe,<sup>1</sup> Mari Ohnuki,<sup>1</sup> Megumi Narita,<sup>1,2</sup> Tomoko Ichisaka,<sup>1,2</sup> Kiichiro Tomoda,<sup>3</sup> and Shinya Yamanaka<sup>1,2,3,4,\*</sup>






19

Ανθρώπινα iPSCs

### **Stem cell cultures for restoration/regeneration**




### **IPS (Induced Pluripotent Stem cells)**


#### IPS:

"Adult cells that have been genetically reprogrammed to an embryonic stem cell–like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells."


### **Stem cell cultures for research and therapies**




### Immune cell isolation and culture




### Immune cell culture




Adaptive and innate immune systems featured in the work of Paul Ehrlich and Ilya Metchnikov, who were awarded the Nobel Prize in Physiology or Medicine in 1908.




1973:







- Gancer
- Transplantation
- Autoimmunity and chronic inflammation
- Allergy
- Vaccines




Banchereau and Steinman, <u>Nature 392</u>: 245-252 (1998) Steinman, <u>Ann.Rev.Immunol. 9</u>: 271-296 (1991) → Expression of programmed death ligand 1 (PD-L1). The interaction of PD-L1 with PD-1 receptors on T cells inhibits their antitumor activity.


<u>Pembrolizumab</u> and <u>nivolumab</u> are monoclonal antibodies (mAbs) that block the PD-1 interaction with PD-L1 can restore antitumor responses.

<u>Ipilimumab</u>, which blocks cytotoxic T lymphocyte antigen-4 (CTLA-4), another immune checkpoint inhibitor, is also effective against tumors.

→ Tumor immunotherapy with these antibodies results in objective responses and prolonged survival in patients e.g. with metastatic melanoma.



### **Immune cell cultures for cancer treatment**




- NK cell culture with cytokines for activation.

- DC vaccination: Dendritic cell culture for encounter and maturation with neoantigens derived from patient's tumor.

- T regulatory (Treg) cell culture to "ease" their suppressive phenotype and expand them.

- CART cell therapy:
T cell engineering and expansion
to induce their anti-tumor effective
phenotype- tumor related
TCR specificity.

- CART cell therapy: T cell engineering and expansion to induce their anti-tumor effective phenotype- tumor related TCR specificity.




### **Immune cell cultures for vaccine development**

### **ELISPOT** assay:

### assay to determine cytokine producing cells



#### **ELISpot Assay Procedure**



#### **Example of an experiment of vaccine/cancer immunotherapy development:**


Group	N*	Treatment
Mice:	18	
1	3 (F)	40ug SVLP/PADRE(Cha) + 10ug E7-flanked
2	3 (F)	40ug SVLP/PADRE(Cha) + 10ug E7-flanked + 1ug poly(I:C)
3	3 (F)	40ug SVLP/PADRE(Cha) + 10ug E7-flanked + 10ug poly(I:C)
4	3 (F)	10ug SVLP/PADRE(Cha) + 10ug E7-flanked + 10ug poly(I:C)
5	3(F)	10ug SVLP/PADRE(Cha) + 10ug E7-flanked
6	2 (F)	FP 10μg + poly(I:C) 10μg + IFA (positive ctrl)
7	1 (F)	Naïve

#### ELISPOT at 9 days after 3 weekly immunizations (45h).

#### T cell responses:

E7-flanked-specific

#### **PADRE-specific**




-Bigger spleens with 1ug/mouse of polyI:C. -Bigger spleens/LNs with 10ug/mouse of polyI:C.


Cutoff value:	Confidence:	
12,21		99.9%

#### Monolayer Cell Culture

## **Types of cell cultures:**




### **3D Cell Culture**



#### Hybrids



#### Organotypic Raft Culture



Organ-on-a-Chip


de Dios-Figueroa et al. Biomedicines, 2021.

e.g. cancer cell cultures:		Advantages	Disadvantages
Usability Relevance	2D cell culture	<ul> <li>Standardised protocol</li> <li>Cheap and simple</li> <li>Can be automated</li> <li>Compatible with high-throughput</li> <li>Easily expandable</li> <li>Compatible with various cell types</li> </ul>	<ul> <li>Static conditions</li> <li>No ECM and TME</li> <li>No concentration gradient</li> <li>Homogenous populations</li> <li>Low physiological relevance</li> <li>Not clinically predictive</li> </ul>
	3D cell culture	<ul> <li>Efficacy</li> <li>Drug resistance</li> <li>Cell-cell and cell-ECM interactions</li> <li>Sensitivity similar to in vivo</li> <li>Co-culturing</li> <li>Heterogenous</li> </ul>	<ul> <li>Static environment</li> <li>Low TME mimicry</li> <li>Challenges to automate for high content screening</li> <li>Inefficient waste and nutrient diffusion</li> </ul>
	Mice models	<ul> <li>Efficacy</li> <li>Drug resistance</li> <li>Whole-body pharmokinetics</li> <li>Side effects</li> <li>TME mimicry</li> <li>Genetically modifiable</li> </ul>	<ul> <li>Immunodeficient (PDX)</li> <li>Unable to upscale</li> <li>Engraftment failures</li> <li>Different pathophysiology to humans</li> <li>Long tumour latency</li> <li>Murine microenvironment</li> </ul>
	Clinical trials	<ul> <li>Efficacy</li> <li>Drug resistance</li> <li>Whole-body pharmokinetics</li> <li>Adverse reactions</li> <li>Immune response</li> <li>Route of administration</li> <li>Highly clinically relevant</li> </ul>	<ul> <li>Programs require collaborations between numerous professionals and experts</li> <li>Long-term follow-ups</li> <li>Variable patient retention</li> <li>Challenges in patient recruitment processes</li> <li>Difficulties in setting trials for rare cancers</li> <li>Logistical and financial constraints</li> </ul>


	2D cell culture	3D cell culture		2D cell culture	3D cell culture
		(#337)			
Cell-Cell		<b>2</b>	Stiffness	Untunable - very high (GPa)	Tunable - low (kPa)
Cell-ECM	Limited cell-cell interaction	Surrounding cell-cell interaction	Soluble gradient	Absent	Waste CO <sub>2</sub> Present
Cell adhesion	No cell-ECM interaction	Cell-ECM interaction	Drug resistance	Non-representative	Sensitivity similar to in vivo
Mobility	Restricted on 2D plane	Dispersed in 3D	Cell cycle stage	Cells all at same stage	Proliferative zone Quiescent zone Necrotic zone Cells at various stages
	Uninhibited dispersion and migration	Sterically hindered dispersion and migration	Phenotypic diversity		
Scaffold	Glass or polystyrene	Physical structure with matrix			Diverse
Modification		MMP-cleavage Adhesive peptides	Law et al. Frontiers Oncology, 2021.		
	Non-modifiable sites	Modifiable sites			

3D Culture Techniques	Suspension Culture	Hydrogel Scaffold	Organ-on-chip	3D bioprinting
Advantages	<ul> <li>Standardised protocols</li> <li>Cheap and simple</li> <li>Can be automated</li> <li>Adaptable for high-throughput</li> <li>Replicable</li> </ul>	<ul> <li>Mimics TME</li> <li>Relatively cheap and simple</li> <li>Can be automated</li> <li>Adaptable for high-throughput</li> <li>Versatile application and hydrogel availability</li> <li>Tunable properties</li> </ul>	<ul> <li>Dynamic fluidics and perfusion</li> <li>Simulate physiological processes (eg heartbeat)</li> <li>Engineered vascularisation</li> <li>Precise control over microenvironment</li> <li>Model drug delivery systems</li> </ul>	<ul> <li>High precision and resolution (100um)</li> <li>Construct highly complex tissue structure</li> <li>Can be automated</li> <li>Fine tuning of tissue architecture and size</li> <li>Various bioinks available</li> </ul>
Disadvantages	<ul> <li>Simple TME</li> <li>Static</li> <li>Inefficient nutrient and waste diffusion</li> <li>Spheroid sizes can vary depending on technique</li> </ul>	<ul> <li>Simple architecture</li> <li>Batch-to-batch variability (Natural hydrogels)</li> <li>Require biofunctionalisation (Synthetic hydrogels)</li> <li>Static</li> <li>Inefficient nutrient and waste diffusion</li> </ul>	<ul> <li>High expertise barrier</li> <li>Difficult to upscale</li> <li>Requires specialised equipments</li> <li>Not suitable for long-term experiments</li> </ul>	<ul> <li>High expertise barrier</li> <li>Difficult to upscale</li> <li>Expensive</li> <li>Requires specialised equipments</li> <li>Cell viability can vary depending on technique</li> </ul>

## Three-Dimensional (3D) Cell Culture (Microphysiological-MPS) Platforms as Drug Development Tools




## Adult human organoids




# "Epithelial-only" organoid culture of diverse human tissues





### Many others




Quality Control Criteria to Ensure the Reproducibility of Liver Microphysiological Systems and Engineered Heart Tissues

٠

Trovafloxacin (Hepatotoxic)


Levofloxacin (Not Hepatotoxic)






Similar Results Between Two Sites


Similar Results Within a Site When Using Different Batches of Kuppfer Cells







 Identified Quality Control Criteria for Kuppfer Cells Engineered heart tissues (EHTs) recapitulate the 3D nature of heart muscle tissue (e.g., contractile alignment), as shown on the blood vessels, (BVs). By immobilizing these tissues between force sensors, researchers analyzed drug-induced variations in the contractility of these platforms and derived functional parameters.









#### Article


Human-iPSC-Derived Cardiac Stromal Cells Enhance Maturation in 3D Cardiac Microtissues and Reveal Non-cardiomyocyte Contributions to Heart Disease





- Simple
- Works using
- cryopreserved cells
- Low tech 6 41

### **Bone organoids**



# Growing organoids from clinical cancer specimens


Law Andrew M. K., Rodriguez de la Fuente Laura, Grundy Thomas J., Fang Guocheng, Valdes-Mora Fatima, Gallego-Ortega David

Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies

Frontiers in Oncology 2021

**Over 90% of potential anti-cancer drug candidates results in translational failures in clinical trials**. The main reason for this failure can be attributed to the non-accurate pre-clinical models that are being currently used for drug development and in personalised therapies. To ensure that the assessment of drug efficacy and their mechanism of action have clinical translatability, the complexity of the tumor microenvironment needs to be properly modelled. 3D culture models are emerging as a powerful research tool that recapitulates in vivo characteristics. Technological advancements in this field show promising application in improving drug discovery, pre-clinical validation, and precision medicine. In this review, we discuss the significance of the tumor microenvironment and its impact on therapy success, the current developments of 3D culture, and the opportunities that advancements that in vitro technologies can provide to improve cancer therapeutics.

# Patient-Derived tumor Organoids (PDOs) from diverse neoplasms



HCM

# PDO tumor organoids recapitulate fibroblast stroma

Colon adenoCa PDO

tumor DAPI epithelium E-cad SMA \_ tumor stroma Fresh surgical tumor epithelium tumor Organoid, d14 stroma


Lung adenoCa PDO



### Chips Lined by Cells from COPD Patients (COPD = Chronic Obstructive Pulmonary Disease)





# Human COPD Exacerbations Recapitulated On-Chip



# **Cigarette Smoke Exposure in Airway Chips**

(KAMBEZ BENAM et al. Cell Syst. 2016)
















GYPTRI

A.P.IPLA

PILLEY CYBRO CHI CYBRO CHI CHI CHI CHI ALDHI ALI

# Cigarette Smoke:




# Take Home Message

- Human Organ Chips are more than potential animal replacements
- They are also Mechanistic Drug Discovery Tools that
  - can provide new insight into human pathophysiology
  - can be combined with advanced analytical approaches
  - enable rapid drug repurposing
  - accelerate discovery of novel therapeutics

0

# MPS DB: The BioSystics Analytics Platform

# An Integrated Database, Analytics and Modeling Platform



# COVID-19 Disease Model Portal Provides Easy and Rapid Access to a Wide Range of Disease Resources

11.2	Studies - Analysis - Models - C	Compounds+ Diseases+ Cells+ About+ Help Feedback mes23
ine Dravia	<ul> <li>One way 56V0.19</li> </ul>	COVID-19 Portal View Other Discesses
		COVID-19 General Information
		umental Models Components Disease Data and Analysis MP.5 Data and Analysis
Inowhide Pa	ge Description	
overnment S	Literature Sources News	MPSCoRe
dai/fh		
41 emer	supplier	Description
INC CONTRACT	supplier Centers for Disease Control and Prevention (CDC)	Description Calchocard of COVID TV cakes and deaths in the United Hates
ana azavia Iala Tracker ana aravia	Centers for Disease Control and Prevention	
SING GERMAN Selle Tracker Sing Franker Sing Franker Sing Franker	Centers for Disease Control and Prevention (CDC) Centers for Disease Control and Prevention	classificand of COVID TV cases and deaths in the United Hates.
Stoc souves held Tracker stoc souves o too keessa foremarkers website Suvenment	Centers for Disease Costor and Prevention (CDC) Centers for Disease Costor and Prevention (CDC) Centers for Disease Costor and Prevention (CDC) and Prevention	calabdeard of COVID The cases and deaths in the United States, information on COVID The Initial States, including general information and sites additional information sources
Anne A Stor Conversion Selection of the Anno Control Alemann Seveniment A Canadoa A Cali SARS- Seveniment A Cali SARS- Seveniment A Cali SARS- Seveniment	Centers for Essease Costol and Investion (CDC) Senters for Essease Costol and Prevention (CDC) Senters for Essease Costol and Prevention (CDC) and Redenal Emergency Management Agency (FEMA)	Calabdoard of COVID-19 in Canada, including the number of lests performed, total spect, active cases, recovered, and easts, and inker to information regarding the curves of lests performed, total cases, active cases, recovered, and deasts, and links to information regarding the curves statistics, vacuum and any sectors.

### Extensive links to information on:

- General COVID-19 information
  - Including literature hubs
- COVID-19 disease biology
- Experimental models
  - Both in vitro and in vivo
- Components to implement COVID-19 studies
  - Direct links to vendor sources
- Preclinical and clinical data
- Computational modeling resources
- COVID-19 data in the MPS-Db

### Designed to be a central repository for sharing all COVID-19 experimental data

# **iPSC** Portal

- Resource that allows users to share information about available iPSC-derived cells
- Resource for finding available iPCS and iPSC derived cells that can be used for specific applications such as the development of COVID-19 experimental models
- Provide information about the characteristics of the cells
  - Mutation status
  - Maturity level
  - Engineered features
  - Etc.
- Provide information and links to obtain the cell samples
- Provide information on how to use the cells
  - Differentiation protocols
  - Culturing protocols

Provide information needed to quickly identify and decide on an appropriate iPSC sample or iPSC derived cell for your model, where to obtain the cells, and how to use them.

### ach iPS-cell instance include:

### Characteristics of the iPSCs

- Differentiated cell type(s)
- Differentiated phenotypes
- Differentiated maturity level
- Functional profiles

### Patient profile

- Demographic
- Known disease conditions
- Genomic abnormalities

### Source of cells

- Vendor
- Collaborator
- Others

### Protocols

- Isolation of patient cells (e.g. skin, blood, other cells)
- Differentiation to target cell type
- Preparation for model

### **Established applications**

- Healthy tissue/organ model(s)
- Disease tissue/organ model(s)

# Neutralization Assays

Advantages versus Drawbacks

- Long history, many options
- Can be automated for routine use
- Derive activity-concentration relationships
- No animal use




- Simplified models (one cell line)
- No spatial/temporal information
- Converting active concentration(s) to dose can be a challenge
  - i.e. pregnancy

MPS as a bridge between neutralization and *in vivo* assays


# In vitro Models of Placenta Barrier: Stepwise Approach





# In v?.ro Models of Placenta Barrier: Co-Cultures of Placental Cells






# Human<sup>©</sup> Jased Placental Barrier MPS for ZIKV Infection

**п.**//

- · Compartment 1: Replicate placental barrier
- Compartment 2: Fetal compartment containing tissues susceptible to ZIKV infection (neurospheres)
- · Treat placental barrier with ZIKV with and without antiviral Ig
  - Monitor placental cytotoxicity, metabolic function, transcytosis and pro-inflammatory signaling molecules
  - · Monitor toxicity at the fetal compartment




# **Considerations when Submitting MPS Derived Data**


### Tab. 1: Aspects to consider when evaluating a new technology

- Does an assay provide data that can be used to answer fundamental drug development questions?
- Is the assay mature enough?
  - Is the platform stable (e.g. biologic function, timeframe)?
  - Are cells available and characterized?
- What endpoints are being measured?
  - Are they <u>predictive</u> of *in vivo* effects?
  - Are they translatable to human?
- Has scientific validity been shown?
  - Is the method reproducible?
  - What test compounds have been assessed?
    - Has data been compared with in vivo data?
    - What positives and negatives were used?
- Has the applicability domain been defined?
  - Have the compounds that the assay can assess/not assess been defined?
- Have criteria for success been defined and met?
  - What is the accuracy, sensitivity, and specificity?

# Proof-of-concept System Comparison




- Test novel therapeutics (e.g. humanderived synthetic Ab) in MPS models and compare with pre/clinical data.
- Side-by-side evaluation of low and high complexity models through comparison of the following data:
  - In vitro cell culture systems
  - Organ-Chip technology (lung airway models)
  - Low-level animal model (golden hamster)
  - Human data from clinical trials
- Led by NIAID/IRF, partially supported by DoD (training) and NICEATM (chips, study design assistance)



# Brain organoid applications

# BrainSpheres: iPSC-derived human organotypic brain cultures




- All cell types but micro-glia
- 350 um diameter
- Reproducible in size and composition
- Myelination
- Genetic background from patient iPSC




# iPSC-derived human organotypic brain cultures





# Myelination

- 40% axons myelinated
- Allows studying de- and re-myelination





International Journal of Molecular Sciences Int. J. Mol. Sci. 2021, 22, 9473

#### Article

### Human IPSC-Derived Model to Study Myelin Disruption

Megan Chesnut<sup>1</sup>, Hélène Paschoud<sup>2</sup>, Cendrine Repond<sup>2</sup>, Lena Smirnova<sup>1</sup>, Thomas Hartung<sup>1,3</sup>, Marie-Gabrielle Zurich<sup>2,4</sup>, Helena T. Hogberg<sup>1,\*</sup> and David Pamies<sup>1,2,4,\*</sup>



International Journal of Molecular Sciences

Int. J. Mol. Sci. 2021, 22, 7929

64

Review

### Human Oligodendrocytes and Myelin In Vitro to Evaluate Developmental Neurotoxicity

Megan Chesnut 1, Thomas Hartung 1.2, Helena Hogberg 1.\* and David Pamies 1.3.4.\*()

# Brain organoids a versatile tool

Developmental neurotoxicity, DNT

Organ-on-a-chip, MEAs

Myelination

Autism

Gene x environment interactions

Neurodegeneration, .e.g. Parkinson's, ALS

Cancer research

Infectious diseases (Zika, JC, Dengue, SarS-Cov2



ALTEX preprint published June 26, 2020 doi:10.14573/altex.2006111

#### nort communication

### fectability of Human BrainSphere Neurons Suggests eurotropism of SARS-CoV-2

Korin Bullen<sup>1,\*</sup>, Helena Therese Hogberg<sup>2,\*</sup>, Asli Bahadirli-Talbott<sup>1</sup>, William R. Bishai<sup>1</sup>, Thomas rtung<sup>2,3,4</sup>, Casey Keuthan<sup>5</sup>, Monika M. Looney<sup>1</sup>, Andrew Pekosz<sup>4</sup>, July Carolina Romero<sup>2</sup>, Fenna C. M.


#### FINANCIAL TIMES

TOME WORLD US COMPANIES TOOM HARRETS GRAPHERS OFFICER WORLS CAREED LIFE & AFTS HOW TO SPEND IT


CORONAVIRUS BUSINESS UPDATE Get 30 days' complementary access to our Coronevirus Business



#### Latest an Coronantrus treatment



And the New Annu




its the manufacture of surrors t



#### Coronavirus could infect human brain and replicate, US study shows

Johns Hopkins University research adds to concern about poorly understood neurological symptome






Presence of ACE2 receptor at all stages of mini-brain development

Some neural cells infected

Replication shown by PCR and confocal microscopy

# **RUMI'S HUMAN MINI-ORGAN MODELS**




RumiViro's platform provides fast and scalable access to reproducible physiological human tissues to model viral disease. 67

# **BIOENGINEERING: BUILDING THE RIGHT TISSUE**


### Micro-patterning technologies for exquisite control of tissue organization

### Breakthrough#1: Standardization

Regular stem cell cultures are messy




RUMI's Micropatterned stem cells are organized



### Breakthrough#2: Physiological Organization

Differentiating stem cells self-organize under confinement to create complex yet reproducible tissues




### Standardized geometrical confinement induces robust self-organization of physiological human mini-organs.

High impact publications from the founder's labs: Nature Methods, 2014; Dev Cell, 2016; Nature Protocols, 2016; Nature Biotech, 2019


# RUMI'S SOLUTION: WELL-DEFINED, SCALABLE, REPRODUCIBLE

Current 3D organoids are heterogeneous and variable → Not well-adapted to drug discovery Ex: lung organoids

RUMI's Targeted reconstruction Large image data banks



Deep learning of quantitative disease features, and drug's potential



Drug efficacy
 Drug cytotoxicity

· variant stratification


Breakthrough#3: Quantitative phenotypic analysis using AI

Core technology protected by a suite of 3 patents


Unique opportunity for quantitative analysis, at scale, of healthy and infected human tissues + screening of large chemical libraries 69

# MINI-LUNGS RECAPITULATE COVID19 DISEASE

### RumiViro's mini-lungs



# DEVELOPING BROAD-SPECTRUM HOST-BASED THERAPEUTICS



Broad-spectrum antivirals for respiratory viral infection
 Coronaviruses, paramyxoviruses, orthomyxoviruses, rhinoviruses, and pneumoviruses

mini-kidneys



Broad-spectrum antivirals for acute viral kidney injury
 Polyomaviruses, HIV, flaviviruses, CMV, and parvoviruses

71

Mini-organs allow for the identification of tissue-targeted host-based therapeutics at scale

### The end.

Thank you!

For further questions or lab visit: 6972212037